Clinical Trials Logo
  1. Home
  2. Hypertension
  3. NCT06052748
  4. Details
NCT06052748 Clinical Trial

A Study to Evaluate the Efficacy and Safety of AD-223

Hypertension,Essential Clinical Trial

Official title:
A Multicenter, Randomized, Double-blind, Active-control, Phase III Study to Evaluate the Efficacy and Safety of AD-223A and AD-223B Combination Therapy in Patients With Essential Hypertension

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT06052748
Other study ID # AD-223P3
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date March 2024
Est. completion date February 2025

Study information
Verified date January 2024
Source Addpharma Inc.
Contact Kyung Tae Kim, D.V.M
Phone 82-031-891-5661
Email ktkim@addpharma.co.kr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of AD-223

Description:

Condition or disease : hypertension

Recruitment information / eligibility
Status Recruiting
Enrollment 486
Est. completion date February 2025
Est. primary completion date February 2025
Accepts healthy volunteers No
Gender All
Age group 19 Years and older
Eligibility Inclusion Criteria: - Signed informed consent - Other inclusions applied Exclusion Criteria: - Orthostatic hypotension with symptom - Other exclusions applied

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• AD-223A
PO, Once daily(QD), 8weeks
• AD-223B
PO, Once daily(QD), 8weeks
• AD-223C
PO, Once daily(QD), 8weeks
• AD-223A Placebo
PO, Once daily(QD), 8weeks
• AD-223B Placebo
PO, Once daily(QD), 8weeks
• AD-223C Placebo
PO, Once daily(QD), 8weeks

Locations
Country Name City State
Korea, Republic of Hanyang University Hospital Seoul

Sponsors (1)
Lead Sponsor Collaborator
Addpharma Inc.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome
Type Measure Description Time frame Safety issue
Primary Change rate of MSSBP Change from baseline in mean sitting systolic blood pressure Baseline, Week 8
See also
  Status Clinical Trial Phase
Completed NCT05086549 - An Observation Study to Evaluate the Renoprotective Effect of Fimasartan in Patients With DKD and Proteinuria
Recruiting NCT05086523 - Cardiac Neuromodulation Therapy (CNT) "Washout" Sub-Study Phase 1/Phase 2
Active, not recruiting NCT03503773 - The TARGET BP OFF-MED Trial Phase 2
Not yet recruiting NCT04082091 - Screening, Early Referral and Lifestyle Tailored E_prescription for Cardiovascular Prevention
Recruiting NCT06019598 - Licorice and Home Blood Pressure, Additional Study N/A
Completed NCT04495231 - Sympathetic Activity and Cardiometabolic Complications
Completed NCT04119999 - A Cardiosleep Research Program on Obstructive Sleep Apnea, Blood Pressure Control and Maladaptive Myocardial Remodeling N/A
Recruiting NCT04505618 - Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease N/A
Recruiting NCT04863508 - Wearable Blood Pressure Devices to Identify Masked Uncontrolled Hypertension.
Completed NCT05185297 - Recreational Futsal for Controlled Hypertension N/A
Completed NCT03855605 - Diagnosis of Hypertension by Home Blood Pressure Monitoring
Completed NCT03901183 - Plant-based Nutrition for Patients With Cardiovascular Risk Factors N/A
Recruiting NCT03206814 - Improving Hypertension Control in CHina and ARGEntina With a Mobile APP-based Telecare System N/A
Recruiting NCT06343246 - Functional Inspiratory Muscle Training in Patients Diagnosed With Hypertension N/A
Completed NCT06359873 - Left Atrial Enlargement: A Crucial Indicator for Identifying Atrial Fibrillation in Patients With Hypertension
Recruiting NCT04565548 - Hypertension Treatment Adherence Improving Trial N/A
Recruiting NCT06205628 - Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension Phase 1
Recruiting NCT04613193 - Blood Pressure Reduction in Patients With Asymptomatic Aortic VALVE Stenosis N/A
Completed NCT03841383 - Association Between Coronary Flow Reserve and BH4 Levels in High CV Risk
Recruiting NCT05413057 - An OS to Evaluate Effectiveness and Safety of Fixed-dose Combinations of FMS/AML or FMS/AML/HCTZ